ETON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eton Pharmaceuticals's revenue per share for the three months ended in Mar. 2024 was $0.31. Eton Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.33.
During the past 12 months, the average Revenue Per Share Growth Rate of Eton Pharmaceuticals was 37.90% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 751.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Eton Pharmaceuticals's Revenue per Share or its related term are showing as below:
During the past 7 years, Eton Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 751.30% per year. The lowest was 150.10% per year. And the median was 450.70% per year.
The historical data trend for Eton Pharmaceuticals's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Revenue per Share | Get a 7-Day Free Trial | 0.05 | - | 0.87 | 0.85 | 1.23 |
Eton Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Revenue per Share | Get a 7-Day Free Trial | 0.21 | 0.46 | 0.27 | 0.28 | 0.31 |
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Eton Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue Per Share (A: Dec. 2023 ) | = | Revenue (A: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2023 ) |
= | 31.642 | / | 25.645 | |
= | 1.23 |
Eton Pharmaceuticals's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as
Revenue Per Share (Q: Mar. 2024 ) | = | Revenue (Q: Mar. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Mar. 2024 ) |
= | 7.966 | / | 25.763 | |
= | 0.31 |
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals (NAS:ETON) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Eton Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
David Krempa | officer: Chief Business Officer | 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Sean Brynjelsen | director, officer: President & CEO | C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
James R. Gruber | officer: Chief Financial Officer | 618 AMES STREET, LIBERTYVILLE IL 60048 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
William Wilson Troutman | officer: CFO, Treasurer & Secretary | 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Imprimis Pharmaceuticals, Inc. | 10 percent owner | 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
Jennifer Mckie Adams | director | 5410 TENNESSEE AVE, NASHVILLE TN 37209 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Mark L Baum | director | C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 08-23-2023
By GuruFocusNews GuruFocusNews • 12-20-2021
By Marketwired • 06-28-2023
By GuruFocusNews GuruFocusNews • 04-11-2022
By PurpleRose PurpleRose • 07-18-2022
By Marketwired • 07-02-2023
By PurpleRose PurpleRose • 07-14-2022
By PRNewswire • 07-03-2023
By Stock market mentor Stock market mentor • 01-11-2023
By GuruFocusNews GuruFocusNews • 05-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.